Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.16
−$0.54 · -31.76%
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Previous close
$1.16
−$0.54 · -31.76%
Regular session · ET · Market data may be delayed.
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Day range
Current $1.16
52-week range
Current $1.16
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
33
Expensive
Sentiment
59
Mixed
Risk
63
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Day range
Current $1.16
52-week range
Current $1.16
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 49.36K USD | 51.07K USD | 57.43K USD | 119.62K USD | 2.53K USD |
| Gross profit | −49.36K USD | −51.07K USD | −57.43K USD | −119.62K USD | −2.53K USD |
| Research and development | 2.05M USD | 1.37M USD | 1.53M USD | 4.42M USD | 635.4K USD |
| Selling, general, and administrative | 3.57M USD | 4.32M USD | 4.71M USD | 4.47M USD | 2.98M USD |
| Operating expenses | 5.62M USD | 5.69M USD | 6.24M USD | 8.88M USD | 3.61M USD |
| Interest income | 132.9K USD | 271.22K USD | 59.09K USD | — | — |
| Interest expense | 19.54K USD | 36.16K USD | — | 20.76K USD | — |
| Depreciation and amortization | 49.36K USD | 51.07K USD | 57.43K USD | 119.62K USD | 2.53K USD |
| Operating income | −5.67M USD | −5.74M USD | −6.29M USD | −9M USD | −3.61M USD |
| Net income | −3.86M USD | −5.25M USD | −8.61M USD | −9.93M USD | −3.66M USD |
Company facts updated Sep 7, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 21, 2026 | 1:10 | — | — |
Stock split | Dec 15, 2025 | 1:40 | — | — |
Stock split | Nov 28, 2023 | 1:30 | — | — |
Stock split | Oct 3, 2022 | 1:30 | — | — |
Effective May 21, 2026
1:10
Effective Dec 15, 2025
1:40
Effective Nov 28, 2023
1:30
Effective Oct 3, 2022
1:30
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
